Introduction
============

Pancreatic cancer is a highly malignant tumor type of the digestive tract that is ranked as the fourth leading cause of cancer-associated mortality ([@b1-ol-0-0-10444]), with an estimated 55,440 new cases and an estimated 44,330 mortalities in the USA in 2018 according to statistics from Surveillance, Epidemiology, and End Results ([@b2-ol-0-0-10444]). Its aggressive biological properties, lack of early symptoms and rapid spread to surrounding organs lead are responsible for the high mortality rate ([@b3-ol-0-0-10444]). Furthermore, the treatment of pancreatic cancer is limited due to difficulties associated with surgical removal, and poor sensitivity to radiotherapy and chemotherapy ([@b4-ol-0-0-10444]--[@b6-ol-0-0-10444]). Therefore, identification of therapeutic targets is urgently required to improve patient outcome ([@b7-ol-0-0-10444]).

It has been reported that β-catenin, a versatile protein that mediates intercellular adhesion and gene expression, is abnormally expressed in pancreatic cancer ([@b8-ol-0-0-10444]). As the transcriptional cofactor of β-catenin, transcription factor 7 like 1 (TCF7L1), also termed transcription factor 3, is a member of the mammalian TCF/LEF family. Nuclear DNA-binding TCF/LEF proteins and β-catenin represent key components of the canonical branch of the Wnt signaling pathway, which serves a key role in pancreatic cancer carcinogenesis ([@b9-ol-0-0-10444],[@b10-ol-0-0-10444]).

Once the Wnt pathway is activated, β-catenin accumulates in the cytoplasm and enters the nucleus, where it engages DNA-bound TCF transcription factors and subsequently regulates the transcription of downstream target genes ([@b11-ol-0-0-10444]). It is understood that β-catenin and TCF7L1 are pivotal proteins in the Wnt/β-catenin pathway; therefore, the genes they regulate may be drug targets for pancreatic cancer ([@b12-ol-0-0-10444]).

In recent years, microarray and high throughput sequencing technologies have widely been used to explore the genetic characteristics of tumorigenesis, which may promote the development of diagnostic and treatment strategies ([@b13-ol-0-0-10444]). Bioinformatics research methods are required to handle large sample data; therefore, different databases have been established to provide convenience for research ([@b14-ol-0-0-10444],[@b15-ol-0-0-10444]). In the present study, the gene expression profiles GSE57728, an array focused on β-catenin, and GSE90926, an array developed by high throughput sequencing regarding TCF7L1, were downloaded from the Gene Expression Omnibus (GEO) and analyzed to obtain the differentially expressed genes (DEGs) between pancreatic control groups and experimental groups. Clustering analysis, and functional and pathways enrichment analysis were performed to identify the associations and functions of the DEGs. In addition, a protein-protein interaction (PPI) network was constructed, and overall survival (OS) and promoter analyses was performed, to identify the associated key genes and pathways downstream of the β-catenin-TCF7L1 complex in pancreatic cancer cells.

Materials and methods
=====================

### Collection and inclusion criteria of the studies

The GEO database ([www.ncbi.nlm.nih.gov/geo/](www.ncbi.nlm.nih.gov/geo/)) was searched for the following keywords: 'pancreatic cancer' (study keyword), 'β-catenin' (study keyword), 'Homo sapiens' (organism) and 'Expression profiling by array or sequencing' (study type). This search revealed seven studies. The inclusion criteria for the studies were as follows: i) Samples were required to be in two groups, including the control group and the experimental group, ii) the sample count needed to be \>10, iii) β-catenin or TCF7L1 in the experimental group should be overexpressed or inhibited, and iv) sufficient information had to be present to perform the analysis. Consequently, GSE57728 ([@b16-ol-0-0-10444]) was downloaded for analysis regarding β-catenin and GSE90926, which was contributed by Dr David Dawson (Dawson Laboratory, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA), was downloaded for analysis regarding TCF7L1.

### Microarray data and validation

Two gene expression profiles (GSE57728 and GSE90926) were downloaded from the GEO database. The array data regarding β-catenin knockdown in GSE57728 included 16 samples, from this the present study selected two control samples with control small interfering RNA (siRNA) transfection and two experimental samples with β-catenin siRNA transfection for analysis. Similarly, the sequencing data regarding TCF7L1 knockdown in GSE90926 included 12 samples and the current study selected three control samples with control siRNA transfection and three experimental samples with TCF7L1 siRNA transfection for further analysis. Subsequently, a microarray assay regarding β-catenin knockdown was conducted to confirm the results from the microarray data downloaded from the GEO database. This was performed based on previous studies in which relevant results regarding the Wnt pathway in pancreatic cancer were revealed, including the identification of FH535 as a small-molecule inhibitor of the Wnt/β-catenin signaling pathway ([@b10-ol-0-0-10444],[@b17-ol-0-0-10444]). FH535, as a classic inhibitor of the β-catenin pathway which could repress pancreatic cancer cell growth and metastasis, played the same role as siRNA in the inhibition of the β-catenin pathway. Sample preparation and processing were performed as described in the GeneChip Expression Analysis Manual (Agilent Technologies, Inc., Santa Clara, CA, USA). Differentially expressed genes were screened using Agilent 44K human whole-genome oligonucleotide microarrays (Agilent Technologies, Inc.). After obtaining the two completed microarrays with different gene expressions, 10 shared genes were selected randomly and the gene expression levels of the control and experimental groups were compared to confirm that the data downloaded from the GEO database was reliable.

### Data processing

R (version 3.3.3 for Windows; <https://www.r-project.org/>) is a software system used for data processing, computing and mapping based on the different R packages. The limma package was used to identify the DEGs by linear modeling of the genes. P\<0.05 and a fold change \>1.5 or \<0.667 were set as the cut-off criteria. Subsequently, a heat map of DEGs was generated using R and P\<0.05 was set as the cut-off criterion.

### Functional and pathway enrichment analysis, and PPI network construction

Database for Annotation, Visualization and Integrated Discovery (DAVID) provides a comprehensive set of functional annotation tools for investigators to understand the biological meaning behind a large list of genes. FunRich is a stand-alone software tool used predominantly for functional enrichment and interaction network analysis of genes and proteins. The results of the analysis can be depicted graphically in the form of Venn, bar, column, pie and doughnut charts. In the present study, gene ontology (GO) enrichment analysis was performed for the identified DEGs using the FunRich (version 3.1.3 for Windows; <http://www.funrich.org/>) and DAVID databases (version 6.8; <http://david.ncifcrf.gov/>). P\<0.05 was set as the cut-off criterion, however, for the sake of symmetry and sharp contrast, the P-value of several terms was \>0.05. In every figure, eight columns were sorted using Funrich. Pathway enrichment analysis was performed for the identified DEGs using KOBAS (<http://kobas.cbi.pku.edu.cn/>), which is a web server for gene/protein functional annotation and functional gene set enrichment. In addition, the Kyoto Encyclopedia of Genes and Genomes (KEGG; <http://www.kegg.jp/>) database was used, which is an integrated database resource for biological interpretation of genome sequences and other high-throughput data ([@b18-ol-0-0-10444]). P\<0.05 was set as the cut-off criterion. In addition, a PPI network of the DEGs was constructed using the STRING database (<http://string-db.org/>) and Cytoscape (version 3.7.1 for Windows; <http://cytoscape.org/>), which is a commonly used software to generate integrated models of biomolecular interaction networks. A combined score \>0.15 was set as the cut-off criterion. To screen the hub genes, a node degree ≥8 was set as the cut-off criterion.

### Survival analysis of DEGs

Gene expression datasets were downloaded from The Cancer Genome Atlas (TCGA; <http://tcga-data.nci.nih.gov/tcga>) to analyze the prognosis of target DEGs. Data from a total of 178 patients with complete clinicopathological and RNASeq data were collected from the TCGA pancreatic cancer cohort. Clinical characteristics of the 178 patients are presented in [Table I](#tI-ol-0-0-10444){ref-type="table"}, including case ID, sex, year of birth, year of mortality, tumor stage, age at diagnosis measured in days, vital status and time from diagnosis to the last follow-up date or mortality. The patients were divided into two groups according to the expression of a particular gene, including a high expression group and a low expression group. The OS of patients with pancreatic cancer was analyzed using R software and the results were compared using Kaplan-Meier curves on which the P-value was presented. A log-rank test was conducted as the post hoc test.

### Promoter analysis of DEGs

Ensemble (<http://www.ensembl.org/index.html>) is an online website that was used to perform promoter analysis of the DEGs. The eligible transcript of every DEG associated with prognosis was selected and then the 3,000 base pairs 5′ upstream were selected as the promoter. Subsequently, the transcription factors (TFs) site analysis function of Genomatix (<http://www.genomatix.de/solutions/genomatix-software-suite.html>) was used to predict potential TF families and TF binding sites by analyzing the sequence of promoter obtained from Ensemble. Core similarity was set as 1 for an accurate prediction.

Results
=======

### Microarray data and validation

As demonstrated in the [Fig. 1](#f1-ol-0-0-10444){ref-type="fig"}, ten genes that were shared between the original microarray data downloaded from the GEO database and our own microarray data regarding β-catenin knockdown, including CGN, CNN3, DZIP1, EGR1, FBXL17, MDM2, SRXN1, HMOX1 and TMEM2, were selected to confirm the results from microarray data downloaded from the GEO database. The results obtained for samples with β-catenin siRNA transfection and samples treated with FH535 exhibited consistent trends, with the exception of the results for IL32, HMOX1 and TMEM2.

### Identification of DEGs and clustering analysis

A total of 1,784 DEGs, including, 812 upregulated and 972 downregulated genes, were identified from GSE90926 regarding TCF7L1 knockdown. A total of 2,013 DEGs, including 1,000 upregulated and 1,013 downregulated genes, were identified from GSE57728 regarding β-catenin knockdown. Among these DEGs, 88 DEGs were screened out as shared by the two datasets. The upregulated and downregulated DEGs were considered separately when selecting the shared genes. As a result, 37 upregulated and 51 downregulated DEGs were identified ([Fig. 2A and B](#f2-ol-0-0-10444){ref-type="fig"}; [Table II](#tII-ol-0-0-10444){ref-type="table"}). The respective heatmaps of the 88 DEGs were generated by R software ([Fig. 2C and D](#f2-ol-0-0-10444){ref-type="fig"}).

### Functional and pathway enrichment analysis, and PPI network construction

To investigate the function of the DEGs, functional enrichment analysis was performed. Analysis using FunRich software indicated that the DEGs were predominantly enriched in the following biological process terms: Transport, amino acid transport, transcription, cytokine and chemokine mediated signaling pathway, and carbohydrate metabolism ([Fig. 3A and B](#f3-ol-0-0-10444){ref-type="fig"}). In addition, the DEGs were predominantly enriched in following cell component terms: Cytoplasmic cyclin-dependent protein kinase holoenzyme complex, interacted disc, M band and DNA-directed RNA polymerase III complex ([Fig. 3C and D](#f3-ol-0-0-10444){ref-type="fig"}). Furthermore, for molecular function, the DEGs were enriched in the following terms: Transcription factor activity, DNA-directed RNA polymerase activity, amino acid transporter activity, transcription and lipid binding ([Fig. 3E and F](#f3-ol-0-0-10444){ref-type="fig"}).

Using the DAVID database, GO analysis identified that the DEGs were enriched in the following terms: Negative regulation of myofibroblast differentiation, stem cell population maintenance and cellular response to antibiotic ([Fig. 3G](#f3-ol-0-0-10444){ref-type="fig"}; [Table III](#tIII-ol-0-0-10444){ref-type="table"}).

KEGG pathway analysis using KOBAS revealed that the DEGs were significantly enriched in the following terms: RNA polymerase, Wnt signaling pathway and cytokine-cytokine receptor interaction ([Fig. 3H](#f3-ol-0-0-10444){ref-type="fig"}; [Table IV](#tIV-ol-0-0-10444){ref-type="table"}).

The PPI network of DEGs consisted of 58 nodes and 171 edges, including 24 upregulated genes and 34 downregulated genes ([Fig. 3I](#f3-ol-0-0-10444){ref-type="fig"}). As aforementioned, the shared 88 DEGs sorted from the two GSE datasets included 37 upregulated and 51 downregulated genes; however, all shared DEGs were not included in the PPI network as certain genes that were isolated at the edge were removed. Therefore, as presented in [Fig. 3I](#f3-ol-0-0-10444){ref-type="fig"}, 58 shared DEGs were included in the PPI network, in which the red nodes represent the upregulated genes and the green nodes represent the downregulated genes. Furthermore, the most significant hub genes were selected as those with the highest numbers of edges. A total of 15 genes were selected as hub genes, including WDFY2, KIT, EGR1, NSD1, DSTYK, CDK14, MDM2, RPS6KA5, CYP1A1, POLR3B, SMC5, DNAI1, SSH2, TRIM24 and CASK.

### OS analysis

OS analysis was performed using R software to investigate the prognostic value of the 88 DEGs and the results were presented as Kaplan-Meier curves. Among the 37 upregulated DEGs, CASK, IL32, and KRT7 were significantly associated with prognosis. In addition, among the 51 downregulated DEGs, the expression levels of CDK14, CXCL5, CYP27C1, DNAI1, FUBP1, TRIM24 and ZMAT1 were identified to be significantly associated with prognosis ([Fig. 4](#f4-ol-0-0-10444){ref-type="fig"}). Furthermore, among the downregulated DEGs, high expression levels of CXCL5, CYP27C1, FUBP1, CDK14 and TRIM24 were associated with significantly worse overall survival ([Fig. 4](#f4-ol-0-0-10444){ref-type="fig"}), which suggests inhibition of the β-catenin-TCF7L1 complex may result in the downregulation of these five potential oncogenic genes. Notably, CDK14 and TRIM24 were identified as hub genes in the PPI network, which indicates these genes may be the key downstream regulators of the β-catenin-TCF7L1 complex.

### Promoter analysis of DEGs

Promoter analysis of DEGs performed using the Ensemble and Genomatix databases revealed that the predicted TFs of the five DEGs associated with poor OS, including CXCL5, CYP27C1, FUBP1, CDK14 and TRIM24, covered different TF families. Only TFs associated with TCF7L1 were selected to obtain a precise result. As presented in the [Fig. 5](#f5-ol-0-0-10444){ref-type="fig"}, TCF7L1 was identified as a TF of four of the DEGs but not CXCL5. This result suggests that TCF7L1 may not be a TF of CXCL5, however, certain unavoidable errors of the prediction may have occurred. Furthermore, the locations of predicted TF sites of each promoter are demonstrated distinctly in [Fig. 5](#f5-ol-0-0-10444){ref-type="fig"}. Two DEGs, including CDK14 and FUBP1, exhibited only one TF site, whereas, TRIM24 and CYP27C1 possessed two different sites. In addition, the locations of the two TF sites of TRIM24 were separated by \<5 base pairs ([Fig. 5](#f5-ol-0-0-10444){ref-type="fig"}).

Discussion
==========

Pancreatic cancer is a highly lethal type of tumor of the digestive tract as its mortality rate is closely associated with the incidence rate ([@b19-ol-0-0-10444]). The majority of patients with pancreatic cancer exhibit no clinical signs until the disease reaches an advanced stage ([@b20-ol-0-0-10444]). Despite rapid developments in treatment strategies, effective early detective tests and drug targets for pancreatic cancer remain limited ([@b21-ol-0-0-10444]). Therefore, further understanding of the mechanisms underlying pancreatic cancer carcinogenesis is essential to improve prognosis and reduce the mortality rate. With developments in microarray technology, it can be useful to determine the general genetic alterations associated with disease progression, which may provide beneficial insight into the diagnosis, treatment and prognosis of the disease ([@b22-ol-0-0-10444]).

The present study selected two datasets of pancreatic cancer in which β-catenin and TCF7L1 knockdown had been performed separately to identify DEGs. A total of 88 shared DEGs were screened out consisting of 37 upregulated and 51 downregulated DEGs. According to functional and pathway enrichment analysis, the shared DEGs were predominantly involved in transport, transcription, and the cytokine and chemokine mediated signaling pathway process. Furthermore, a PPI network was constructed and 15 genes were selected as hub genes, including WDFY2, KIT, EGR1, NSD1, DSTYK, CDK14, MDM2, RPS6KA5, CYP1A1, POLR3B, SMC5, DNAI1, SSH2, TRIM24 and CASK. According to OS analysis, high expression levels of CXCL5, CYP27C1, FUBP1, CDK14 and TRIM24, which were downregulated by inhibition of the β-catenin-TCF7L1 complex, were associated with worse prognosis. Notably, both CDK14 and TRIM24 were identified as hub genes in the PPI network and were negatively associated with OS, which suggests these two genes may serve key roles downstream of β-catenin-TCF7L1 complex.

CDK14, a member of the cyclin-dependent kinases, is a cdc2-associated serine/threonine protein kinase, which serves a vital role in normal cell cycle progression ([@b23-ol-0-0-10444]). It has been reported that CDK14 may interact with cyclin D3 and human cyclin Y to regulate cell cycle and cell proliferation ([@b24-ol-0-0-10444],[@b25-ol-0-0-10444]). Furthermore, certain reports have suggested that CDK14 also regulates a number of pathways, including the Wnt/β-catenin signaling pathway and phosphoinositide 3-kinase (PI3K)/Akt signaling pathway, and cellular mechanisms to act as an oncogene ([@b26-ol-0-0-10444],[@b27-ol-0-0-10444]). It is understood that the Wnt/β-catenin signaling pathway is a conserved signaling pathway associated with cell proliferation, migration, apoptosis, differentiation and normal stem cell self-renewal ([@b28-ol-0-0-10444]). In the absence of Wnt signaling, the mitosis-specific CDK14-Cyclin Y kinase complex phosphorylates Ser-1490 of LRP5/6, which are co-receptors for Wnt ligands at the G2/M stage, thereby triggering the receptor for Wnt-induced phosphorylation ([@b29-ol-0-0-10444],[@b30-ol-0-0-10444]). Furthermore, a previous study has identified that CDK14 is highly expressed in pancreatic cancer, which promotes the proliferation, migration and invasion of cancer cells ([@b31-ol-0-0-10444]). In addition, this high expression has been observed in a number of other types of malignant tumor, including hepatocellular carcinoma, gastric cancer and breast cancer ([@b26-ol-0-0-10444],[@b32-ol-0-0-10444],[@b33-ol-0-0-10444]). By contrast, knockout or inhibition of CDK14 has been demonstrated to exhibit a benefit on the prognosis of cancer types, including ovarian cancer and breast cancer ([@b32-ol-0-0-10444],[@b34-ol-0-0-10444]). Furthermore, the PI3K/Akt signaling pathway also serves a vital role in cell proliferation, migration, apoptosis and differentiation, and dysregulation of this pathway is common in pancreatic cancer. A previous study demonstrated that knockdown of CDK14 inhibited the proliferation and invasion of pancreatic cancer cells, in addition to the epithelial-to-mesenchymal transition, by suppressing the PI3K/Akt signaling pathway ([@b31-ol-0-0-10444]).

TRIM24, also termed transcription intermediary factor 1-α, is a member of the transcription intermediary factor family and has been confirmed to serve a key role in tumor development and progression ([@b35-ol-0-0-10444],[@b36-ol-0-0-10444]). Furthermore, previous studies have demonstrated that TRIM24 is upregulated in several types of cancer and involved in numerous pathways. For example, certain studies have identified that TRIM24 is overexpressed, and promotes cancer cell growth and invasion in bladder cancer and cervical cancer, possibly via the nuclear factor-κB and PI3K/Akt signaling pathways ([@b36-ol-0-0-10444],[@b37-ol-0-0-10444]). Similarly, it has been reported that TRIM24 can accelerate cell growth and facilitate gastric cancer progression by activation of the Akt pathway ([@b37-ol-0-0-10444]) and the Wnt/β-catenin signaling pathway ([@b38-ol-0-0-10444]). Notably, in contrast to the aforementioned studies that suggest TRIM24 is an important oncogene in tumor development, TRIM24 has been identified to suppress the progression of murine hepatocellular carcinoma ([@b39-ol-0-0-10444]). Therefore, the contradictory role or TRIM24 requires further investigation.

In addition to CDK14 and TRIM24, three other genes downstream of β-catenin-TCF7L1 were revealed to be negatively associated with prognosis including, CXCL5, CYP27C1 and FUBP1. CXCL5, CYP27C1 and FUBP1 were not identified as hub genes in the PPI network; however, these genes may also be target genes that affect OS and respond to the β-catenin-TCF7L1 complex.

FUBP1 encodes far upstream element-binding protein 1; a single stranded DNA-binding protein containing three domains that contribute to c-myc transcriptional regulation by binding to the far upstream element ([@b40-ol-0-0-10444],[@b41-ol-0-0-10444]). As a member of the myc oncoprotein family, c-myc has been confirmed to be associated with oncogenesis ([@b42-ol-0-0-10444],[@b43-ol-0-0-10444]). Therefore, it is not surprising that FUBP1 has also been revealed to be expressed in many types of malignant tissue and promote tumor proliferation and migration, and led to poor prognosis ([@b44-ol-0-0-10444],[@b45-ol-0-0-10444]), which is consistent with the previous study. In addition, FUBP1 has been identified to function as an oncogene by regulating c-myc transcription in tumor progression ([@b46-ol-0-0-10444]). By contrast, the role of FUBP1 tumorigenesis may be c-myc independent, as a previous report demonstrated that knockdown of FUBP1 had no effect on the level of c-myc in hepatocellular carcinoma ([@b44-ol-0-0-10444]). In summary, FUBP1 may serve as a potential drug target due to its significant role in tumorigenesis. A recent study revealed that camptothecin and its analog SN-38, the active metabolite of irinotecan, may serve as a novel therapy for hepatocellular carcinoma by targeting FUBP1 ([@b47-ol-0-0-10444]). In addition, a previous study suggested that miR-16 may suppress FUBP1, both of which were associated with the trastuzumab response in ErbB-2-positive primary breast cancer ([@b48-ol-0-0-10444]).

CXCL5 is a member of the CXC subfamily of chemokines, which are produced locally in tissues. These chemokines function by interacting with specific G protein-coupled receptors, which are mainly expressed on leukocytes ([@b49-ol-0-0-10444]). It is well understood that chemokines serve a key role in infection and inflammation. Similarly, a number of reports have suggested that CXCL5 may contribute to pathogen- and autoimmune-induced inflammatory reactions, and angiogenesis by driving neutrophil recruitment ([@b50-ol-0-0-10444],[@b51-ol-0-0-10444]). Furthermore, CXCL5 has also been confirmed to participate in cancer progression. Previous studies have demonstrated that overexpression of CXCL5 mediates neutrophil infiltration, and promotes cell proliferation and invasion in different types of tumor, including hepatocellular carcinoma and colorectal cancer, which suggests a poor prognosis ([@b52-ol-0-0-10444],[@b53-ol-0-0-10444]). Knockdown of CXCL5 has been revealed to inhibit the proliferation and migration of human bladder cancer T24 cells ([@b54-ol-0-0-10444]). Furthermore, CXCL5 is associated with the PI3K/Akt/glycogen synthase kinase-3β/Snail signaling pathway ([@b55-ol-0-0-10444],[@b56-ol-0-0-10444]) and epidermal growth factor (EGF)-EGF receptor signaling pathway ([@b57-ol-0-0-10444]), which have been demonstrated to serve significant roles in tumorigenesis.

CYP27C1 belongs to the cytochrome P450 superfamily of enzymes, which is understood to catalyze a number of reactions associated with drug metabolism ([@b58-ol-0-0-10444]). However, the number of studies regarding CYP27C1 is very limited. Certain studies have revealed that CYP27C1 can convert vitamin A1 into A2, which could be a switch for visual sensitivity ([@b59-ol-0-0-10444],[@b60-ol-0-0-10444]). However, the other functions of this gene require further investigation.

In conclusion, the genes identified in the current study may serve as potential targets in pancreatic cancer. Furthermore, the associated functions and pathways may also provide information that can assist with the diagnosis and treatment of patients with pancreatic cancer. However, it is undeniable that there is a limitation of the present study due to the lack of experimental validation. In the future, the results predicted by bioinformatics analysis may be verified by advanced research and technology to provide benefits for the clinical outcome of patients with pancreatic cancer. In summary, the genes identified in the present study may provide potential targets for the diagnosis and treatment of pancreatic cancer, and they need to be validated prior to clinical use.
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![Microarray data and validation. Ten shared genes, including CGN, CNN3, DZIP1, EGR1, FBXL17, MDM2, SRXN1, HMOX1 and TMEM2, were selected to confirm the results from microarray data downloaded from the Gene Expression Omnibus database. Microarray analysis was performed to detect the expression of genes of samples transfected with 20 nM control siRNA or β-catenin siRNA in the original microarray data downloaded from GEO database. Microarray analysis was also performed to measure the expression of genes in samples treated with 20 µM FH535 in our own microarray data. The data are presented as the means ± standard deviation. \*P\<0.05 vs. respective control. siRNA, small interfering RNA; KD, knockdown.](ol-18-02-1117-g00){#f1-ol-0-0-10444}

![Identification of DEGS. (A and B) Identification of DEGs in the expression profiling TCF7L1 KD dataset GSE90926 and the β-catenin KD dataset GSE57728. A total of 88 shared DEGs were identified, including 37 upregulated and 51 downregulated DEGs. (C and D) Heatmaps of the shared 88 DEGs of the two GSE datasets were generated by R software. Red indicates upregulation and green indicates downregulation. DEG, differentially expressed gene; KD, knockdown; TCF7L1, transcription factor 7 like 1; siRNA, small interfering RNA; Rep, replication.](ol-18-02-1117-g01){#f2-ol-0-0-10444}

###### 

Functional and pathway enrichment analysis, and PPI network construction. Functional enrichment analysis of the identified DEGs was performed by FunRich with the following three parts: (A and B) Biological processes, (C and D) cell component and (E and F) molecular function. (G) GO analysis of identified DEGs using Database for Annotation, Visualization and Integrated Discovery. (H) Kyoto Encyclopedia of Genes and Genomes pathway analysis of identified DEGs using KOBAS. (I) PPI network of the DEGs consisting of 58 nodes and 171 edges, including 24 upregulated genes (red) and 34 downregulated genes (green). PPI, protein-protein interaction; DEG, differentially expressed gene; GO, gene ontology.
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![Overall survival analysis. Ten DEGs of the 88 DEGs were selected for overall survival analysis, including the upregulated genes CASK, IL32 and KRT7, and the downregulated genes CDK14, CXCL5, CYP27C1, DNAI1, FUBP1, TRIM24 and ZMAT1. Overall survival analysis was performed using R software. DEG, differentially expressed gene.](ol-18-02-1117-g04){#f4-ol-0-0-10444}

![Promoter analysis of DEGs. Five DEGs including, CDK14, CYP27C1, FUBP1, CXCL5 and TRIM24 were analyzed using the Ensemble and Genomatix database to predict their interaction with the transcription factor TCF7L1, which belongs to the LEF-TCF family. The locations of the predicted TCF7L1 sites of each promoter are demonstrated with blue vertical line and numbers. +1 indicates the translation start site. Grey boxes represent exons. DEG, differentially expressed gene; TCF7L1, transcription factor 7 like 1.](ol-18-02-1117-g05){#f5-ol-0-0-10444}

###### 

Clinical characteristics of 178 patients used for overall survival analysis.

  Case ID   Sex      Year of birth   Year of mortality   Tumor stage    Age at diagnosis, days   Alive at last follow-up   Days from diagnosis to mortality   Days from diagnosis to last follow-up
  --------- -------- --------------- ------------------- -------------- ------------------------ ------------------------- ---------------------------------- ---------------------------------------
    1       Male     1929            2011                iib            30,092                   No                        292                                --
    2       Female   1942            --                  iIb            26,179                   No                        375                                1
    3       Male     1970            --                  iib            15,807                   Yes                       --                                 286
    4       Male     1938            --                  ib             27,362                   No                        498                                449
    5       Female   1953            --                  iia            22,131                   Yes                       --                                 438
    6       Male     1947            2012                iib            23,962                   No                        66                                 --
    7       Male     1938            2013                iib            27,082                   No                        652                                --
    8       Female   1938            2014                iib            27,662                   No                        532                                --
    9       Male     1972            --                  ia             14,729                   Yes                       --                                 1,037
  10        Male     1932            --                  iib            29,792                   Yes                       --                                 483
  11        Male     1932            --                  ib             29,631                   Yes                       --                                 7
  12        Female   1938            --                  iib            27,645                   Yes                       --                                 525
  13        Female   1962            --                  iib            18,202                   No                        913                                648
  14        Male     1962            --                  iib            18,357                   Yes                       --                                 920
  15        Male     1949            --                  iib            23,152                   Yes                       --                                 666
  16        Male     1926            2010                iia            29,633                   No                        1,101                              --
  17        Female   1957            2012                iib            20,051                   No                        511                                --
  18        Male     1936            2009                iib            26,085                   No                        1,059                              --
  19        Female   1946            --                  ib             23,406                   Yes                       --                                 1,542
  20        Male     1957            2013                iib            20,133                   No                        607                                --
  21        Male     1941            --                  iib            24,760                   Yes                       --                                 2,285
  22        Female   1940            --                  iib            26,635                   No                        732                                385
  23        Male     1943            --                  ib             24,621                   Yes                       --                                 998
  24        Male     1933            --                  iib            28,174                   No                        661                                240
  25        Female   1936            --                  iib            24,025                   No                        2,036                              1,953
  26        Male     1937            --                  iib            27,453                   Yes                       --                                 743
  27        Male     1965            2012                iib            17,294                   No                        308                                --
  28        Female   1955            --                  iib            20,741                   Yes                       --                                 392
  29        Female   1930            2011                iib            29,585                   No                        153                                --
  30        Male     1964            --                  iib            17,794                   Yes                       --                                 729
  31        Female   1947            --                  iv             24,291                   Yes                       --                                 420
  32        Male     1925            2009                iia            30,571                   No                        480                                --
  33        Female   1932            --                  iii            29,213                   Yes                       --                                 462
  34        Female   1948            --                  iib            23,672                   Yes                       --                                 635
  35        Male     1964            --                  iib            18,059                   Yes                       --                                 404
  36        Male     1938            --                  iia            27,684                   No                        267                                110
  37        Female   1936            --                  iib            27,929                   No                        517                                0
  38        Female   1952            --                  ib             21,732                   Yes                       --                                 1,103
  39        Male     1941            --                  iib            26,028                   Yes                       --                                 80
  40        Female   1939            --                  iia            27,152                   Yes                       --                                 467
  41        Female   1946            --                  iib            22,981                   Yes                       --                                 228
  42        Female   1942            2013                iib            25,920                   No                        627                                --
  43        Male     1946            2012                iib            23,998                   No                        458                                --
  44        Female   1929            2011                iib            29,904                   No                        568                                --
  45        Female   1959            --                  iib            19,064                   No                        593                                20
  46        Female   1928            --                  ia             30,821                   No                        151                                91
  47        Male     1958            --                  iib            19,904                   Yes                       --                                 767
  48        Female   1946            --                  iib            23,868                   No                        596                                21
  49        Male     1952            --                  iib            21,676                   Yes                       --                                 522
  50        Female   1947            2009                iib            22,990                   No                        110                                --
  51        Female   1958            --                  iia            19,839                   No                        299                                28
  52        Male     1936            --                  iib            27,637                   Yes                       --                                 194
  53        Female   1945            2010                iib            23,953                   No                        31                                 --
  54        Male     1939            2013                iib            26,936                   No                        691                                --
  55        Female   1948            --                  iib            22,376                   Yes                       --                                 2,016
  56        Male     1939            --                  ia             26,947                   Yes                       --                                 454
  57        Male     1943            2011                iib            24,078                   No                        1,130                              --
  58        Female   1951            --                  iia            22,090                   Yes                       --                                 840
  59        Female   1965            --                  iib            17,821                   No                        278                                164
  60        Female   1936            --                  iib            28,434                   No                        160                                11
  61        Female   1945            2010                iib            23,580                   No                        603                                --
  62        Male     1926            2011                ia             31,319                   No                        244                                --
  63        Female   1968            --                  i              14,599                   Yes                       --                                 2,741
  64        Male     1954            --                  iib            19,847                   Yes                       --                                 716
  65        Female   1953            --                  ib             22,126                   Yes                       --                                 9
  66        Male     1978            --                  iib            13,127                   Yes                       --                                 245
  67        Male     1947            --                  iia            24,007                   Yes                       --                                 586
  68        Male     1944            2012                iia            24,731                   No                        634                                --
  69        Male     1959            --                  iia            19,677                   Yes                       --                                 671
  70        Male     1943            --                  iv             25,849                   Yes                       --                                 603
  71        Male     1937            --                  iib            27,850                   Yes                       --                                 0
  72        Female   1939            2013                ib             27,128                   No                        144                                --
  73        Male     1938            2010                iib            26,239                   No                        485                                --
  74        Female   1934            2008                iib            26,773                   No                        467                                --
  75        Male     1934            2010                iib            28,074                   No                        143                                --
  76        Male     1963            2013                iib            18,315                   No                        183                                --
  77        Male     1935            2009                ib             26,747                   No                        598                                --
  78        Male     1956            2012                iib            20,641                   No                        277                                --
  79        Male     1940            --                  iib            26,503                   Yes                       --                                 657
  80        Male     1937            --                  iia            28,047                   Yes                       --                                 517
  81        Female   1968            --                  iib            16,255                   No                        470                                247
  82        Female   1933            --                  iib            29,150                   No                        233                                153
  83        Male     1957            --                  iib            20,071                   No                        592                                360
  84        Male     1945            --                  iib            24,150                   No                        614                                361
  85        Female   1954            --                  iib            21,491                   Yes                       --                                 660
  86        Male     1947            2011                iib            23,713                   No                        216                                --
  87        Female   1944            --                  iib            24,891                   Yes                       --                                 491
  88        Male     1962            2011                iib            18,172                   No                        123                                --
  89        Female   1946            --                  iv             24,043                   No                        394                                347
  90        Female   1947            2012                iib            23,431                   No                        460                                --
  91        Male     1936            --                  iib            28,403                   Yes                       --                                 330
  92        Female   1963            --                  iib            18,607                   No                        366                                202
  93        Female   1956            --                  iia            20,316                   Yes                       --                                 969
  94        Female   1929            --                  iib            30,684                   Yes                       --                                 225
  95        Female   1940            --                  iib            26,379                   Yes                       --                                 319
  96        Female   1939            --                  iib            27,295                   No                        393                                127
  97        Male     1945            --                  ib             24,810                   Yes                       --                                 951
  98        Female   1950            --                  iib            23,218                   No                        313                                155
  99        Female   1950            --                  iib            22,413                   Yes                       --                                 4
  100       Female   1942            2011                iib            25,312                   No                        224                                --
  101       Female   1948            2009                iib            21,611                   No                        741                                --
  102       Male     1955            2007                iib            19,287                   No                        61                                 --
  103       Female   1955            2009                iib            19,718                   No                        486                                --
  104       Male     1945            --                  iib            24,864                   Yes                       --                                 431
  105       Male     1939            --                  iib            25,809                   Yes                       --                                 289
  106       Male     1950            --                  iib            22,433                   No                        366                                24
  107       Male     1936            2013                iib            28,239                   No                        95                                 --
  108       Female   1943            --                  iib            25,412                   No                        179                                4
  109       Female   1926            2012                iib            31,393                   No                        481                                --
  110       Male     1946            --                  iib            24,589                   Yes                       --                                 737
  111       Female   1933            2011                iib            28,353                   No                        702                                --
  112       Female   1958            --                  iib            20,366                   Yes                       --                                 33
  113       Female   1950            --                  iib            23,306                   No                        230                                179
  114       Male     1954            --                  iib            21,024                   No                        518                                8
  115       Male     1945            2009                iia            23,703                   No                        117                                --
  116       Female   1922            2007                iib            31,074                   No                        155                                --
  117       Male     1950            --                  iia            22,283                   Yes                       --                                 1,216
  118       Female   1954            --                  iv             21,501                   No                        545                                5
  119       Male     1931            2012                iib            29,674                   No                        120                                --
  120       Male     1957            --                  iia            20,607                   Yes                       --                                 498
  121       Female   1935            2012                iib            27,957                   No                        695                                --
  122       Female   1956            --                  iib            20,858                   Yes                       --                                 395
  123       Female   --              --                  iia            17,628                   Yes                       --                                 584
  124       Female   1949            2013                iib            23,622                   No                        239                                --
  125       Male     1934            --                  iia            28,317                   Yes                       --                                 482
  126       Male     1946            --                  iia            23,760                   Yes                       --                                 314
  127       Male     1946            2010                iib            23,443                   No                        12                                 --
  128       Male     1937            2009                iv             26,216                   No                        619                                --
  129       Male     1930            2010                iib            29,319                   No                        123                                --
  130       Female   1946            --                  ia             24,174                   Yes                       --                                 1,021
  131       Female   1924            --                  iib            32,475                   No                        421                                233
  132       Male     1944            --                  ib             23,791                   Yes                       --                                 1,854
  133       Male     1952            2009                iib            20,984                   No                        334                                --
  134       Male     1950            --                  iia            22,425                   Yes                       --                                 1,287
  135       Female   1951            --                  iib            22,329                   Yes                       --                                 289
  136       Female   1949            --                  ib             23,685                   Yes                       --                                 95
  137       Male     1935            --                  iib            28,454                   No                        308                                0
  138       Male     1946            --                  iib            24,576                   Yes                       --                                 338
  139       Male     1952            --                  Not reported   21,175                   Yes                       --                                 1,794
  140       Female   1956            2012                ib             20,760                   No                        219                                --
  141       Male     1965            --                  iib            16,766                   Yes                       --                                 1,323
  142       Male     1970            --                  iib            15,869                   Yes                       --                                 440
  143       Female   1932            --                  iib            28,554                   Yes                       --                                 1,257
  144       Female   1943            --                  iib            25,214                   No                        378                                16
  145       Male     1939            --                  iib            26,573                   Yes                       --                                 969
  146       Male     1964            --                  iia            17,649                   No                        353                                166
  147       Female   1955            --                  iib            21,484                   Yes                       --                                 463
  148       Female   1963            2011                iib            16,126                   No                        1,502                              --
  149       Male     1941            --                  iib            26,188                   Yes                       --                                 484
  150       Male     1955            2012                iib            20,618                   No                        684                                --
  151       Male     1937            2012                iia            27,600                   No                        293                                --
  152       Male     1942            --                  iia            25,768                   Yes                       --                                 252
  153       Female   1946            --                  ib             22,799                   Yes                       --                                 2,084
  154       Female   1940            --                  iia            26,311                   Yes                       --                                 232
  155       Male     1948            --                  iib            23,801                   Yes                       --                                 287
  156       Male     1942            --                  iii            25,227                   Yes                       --                                 706
  157       Male     1967            2009                iib            15,188                   No                        666                                --
  158       Female   1938            --                  Not reported   26,859                   Yes                       --                                 388
  159       Male     1947            2007                iib            22,148                   No                        145                                --
  160       Male     1939            2013                iib            26,745                   No                        430                                --
  161       Male     1954            --                  Not reported   20,451                   Yes                       --                                 1,942
  162       Male     1954            --                  iib            21,792                   Yes                       --                                 350
  163       Female   1928            2002                iii            26,881                   No                        541                                --
  164       Male     1962            2012                iia            18,475                   No                        128                                --
  165       Female   1942            2011                iia            24,117                   No                        1,332                              --
  166       Female   1950            2013                iib            22,400                   No                        738                                --
  167       Female   1932            --                  iib            29,585                   No                        466                                36
  168       Male     1937            --                  iib            28,013                   Yes                       --                                 8
  169       Female   1949            --                  iia            23,624                   Yes                       --                                 379
  170       Male     1954            --                  iib            21,277                   Yes                       --                                 416
  171       Female   1962            --                  iib            18,129                   Yes                       --                                 1,116
  172       Male     1940            --                  ib             26,167                   No                        236                                0
  173       Female   1959            --                  ib             19,707                   Yes                       --                                 720
  174       Male     1958            --                  iib            19,315                   Yes                       --                                 1,383
  175       Male     1939            --                  iia            26,943                   Yes                       --                                 676
  176       Male     1941            --                  iib            26,129                   No                        365                                329
  177       Male     1937            2013                iia            26,234                   No                        2,182                              --
  178       Male     1940            --                  iib            26,322                   Yes                       --                                 978

Tumor stage was determined according to the 7th Edition of the American Joint Committee on Cancer Staging Manual ([@b61-ol-0-0-10444]).

###### 

Identification of differentially expressed genes.

  Regulation      Genes name
  --------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Upregulated     MMP19, OBSL1, KIT, PDSS1, SYT5, KLHL9, KCNT2, PPL, KRT7, FBXL17, SH2D3C, MR1, C10orf54, IL32, FLG-AS1, SLC9A1, TDRP, GPSM3, CGN, FKBP1A-SDCBP2, CASK, WDFY2, SLC35F3, SLC7A2, EBF4, KCTD18, SLITRK6, IRF9, STC1, CLIC3, SLC6A6, CYP1A1, GATSL2, NOTUM, TP53INP1, CACNA2D1, SPOCK3.
  Downregulated   POLR3G, MNS1, ZMAT1, CXCL5, PMP2, DEPDC1, TRIM24, SRXN1, CYP27C1, GPR180, OSBPL6, DNAI1, DCLRE1A, POLR3B, PCDHGA1, CLUL1, C3orf14, SMC5, EGR1, PDK4, RPS6KA5, CLEC2B, SFXN2, HAGLR, PDCD4, RHEBL1, RRBP1, NFIB, DHX34, UBE2Q2L, EOMES, MDM2, FUBP1, DNAH1, DSTYK, ESX1, TET1, ODF2L, NSD1, SSH2, PTX3, LINC00173, MYCL, TMEM2, GRB14, TNFRSF19, CDK14, FRA10AC1, SOX17, PXYLP1, ZNF618.

###### 

GO analysis of differentially expressed genes in pancreatic cancer.

  Category           Term                                                                               Count   \%            P-value^[a](#tfn2-ol-0-0-10444){ref-type="table-fn"}^
  ------------------ ---------------------------------------------------------------------------------- ------- ------------- -------------------------------------------------------
  GOTERM_BP_DIRECT   GO:1904761\~negative regulation of myofibroblast differentiation                   2       2.272727273   0.009268837
  GOTERM_BP_DIRECT   GO:0019827\~stem cell population maintenance                                       3       3.409090909   0.02259656
  GOTERM_MF_DIRECT   GO:0002039\~p53 binding                                                            3       3.409090909   0.033191281
  GOTERM_BP_DIRECT   GO:0071236\~cellular response to antibiotic                                        2       2.272727273   0.036569485
  GOTERM_BP_DIRECT   GO:0001706\~endoderm formation                                                     2       2.272727273   0.054355943
  GOTERM_BP_DIRECT   GO:0003351\~epithelial cilium movement                                             2       2.272727273   0.058751666
  GOTERM_BP_DIRECT   GO:0071391\~cellular response to estrogen stimulus                                 2       2.272727273   0.058751666
  GOTERM_MF_DIRECT   GO:0000977\~RNA polymerase II regulatory region sequence-specific DNA binding      4       4.545454545   0.059249025
  GOTERM_BP_DIRECT   GO:0070498\~interleukin-1-mediated signaling pathway                               2       2.272727273   0.063127217
  GOTERM_BP_DIRECT   GO:0006885\~regulation of pH                                                       2       2.272727273   0.071818168
  GOTERM_BP_DIRECT   GO:0090280\~positive regulation of calcium ion import                              2       2.272727273   0.071818168
  GOTERM_BP_DIRECT   GO:0071456\~cellular response to hypoxia                                           3       3.409090909   0.07344514
  GOTERM_MF_DIRECT   GO:0001056\~RNA polymerase III activity                                            2       2.272727273   0.074087687
  GOTERM_CC_DIRECT   GO:0005666\~DNA-directed RNA polymerase III complex                                2       2.272727273   0.079265755
  GOTERM_BP_DIRECT   GO:0045089\~positive regulation of innate immune response                          2       2.272727273   0.08042952
  GOTERM_BP_DIRECT   GO:0002690\~positive regulation of leukocyte chemotaxis                            2       2.272727273   0.08042952
  GOTERM_BP_DIRECT   GO:0045892\~negative regulation of transcription, DNA-templated                    6       6.818181818   0.082369804
  GOTERM_BP_DIRECT   GO:0045944\~positive regulation of transcription from RNA polymerase II promoter   9       10.22727273   0.084587325
  GOTERM_CC_DIRECT   GO:0036126\~sperm flagellum                                                        2       2.272727273   0.087239628
  GOTERM_BP_DIRECT   GO:0006366\~transcription from RNA polymerase II promoter                          6       6.818181818   0.090139483

P\<0.05 was set as the cut-off criterion. Count, the number of enriched genes in each term; GO, gene ontology; BP, biological processes; CC, cell component; MF, molecular function.

###### 

Kyoto Encyclopedia of Genes and Genomes signaling pathway enrichment analysis of differentially expressed genes in pancreatic cancer.

  Pathway ID   Term                                     Count   P-value^[a](#tfn3-ol-0-0-10444){ref-type="table-fn"}^
  ------------ ---------------------------------------- ------- -------------------------------------------------------
  hsa03020     RNA polymerase                           2       0.002583461
  hsa05219     Bladder cancer                           2       0.004105174
  hsa04261     Adrenergic signaling in cardiomyocytes   3       0.004711319
  hsa04623     Cytosolic DNA-sensing pathway            2       0.009436485
  hsa05169     Epstein-Barr virus infection             3       0.010969532
  hsa05205     Proteoglycans in cancer                  3       0.011112587
  hsa04260     Cardiac muscle contraction               2       0.013627503
  hsa04060     Cytokine-cytokine receptor interaction   3       0.021708158
  hsa00240     Pyrimidine metabolism                    2       0.023537332
  hsa04668     TNF signaling pathway                    2       0.025617518
  hsa04919     Thyroid hormone signaling pathway        2       0.029094794
  hsa05206     MicroRNAs in cancer                      3       0.029496436
  hsa04120     Ubiquitin mediated proteolysis           2       0.038049532
  hsa04530     Tight junction                           2       0.039046349
  hsa04310     Wnt signaling pathway                    2       0.041069627
  hsa00900     Terpenoid backbone biosynthesis          1       0.049591361

P\<0.05 was set as the cut-off criterion. Count, the number of enriched genes in each term.

[^1]: Contributed equally
